UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
---------------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES AND EXCHANGE ACT OF 1934
April 29, 2002
Date of Report (Date of earliest event reported)
---------------------
NEOTHERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
DELAWARE 000-28782 93-0979187
(State or other Jurisdiction (Commission File Number) (IRS Employer
of Incorporation) Identification Number)
157 TECHNOLOGY DRIVE 92618
IRVINE, CALIFORNIA (Zip Code)
(Address of principal executive offices)
(949)788-6700
(Registrant's telephone number, including area code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
ITEM 5. OTHER EVENTS.
On April 29, 2002, NeoTherapeutics, Inc. issued a news release announcing the
preliminary results of the Company's recently completed clinical trial of
Neotrofin(TM) in Alzheimer's disease. The text of the press release is set forth
in Exhibit 99.1 attached to this report and incorporated herein by this
reference.
ITEM 7. EXHIBITS
Exhibits:
99.1 Press Release dated April 29, 2002.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
NEOTHERAPEUTICS, INC.
Date: April 29, 2002 By: /s/ Samuel Gulko
-------------------------------------
Name: Samuel Gulko
Title: Senior Vice President Finance,
Chief Financial Officer,
Secretary and Treasurer
Exhibit
Number Document Description
------- --------------------
99.1 Press Release dated April 29, 2002